Laddar…
Academic Journal
Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab
Yuki Kasahara, Ken Saijo, Reio Ueta, Ryunosuke Numakura, Keiju Sasaki, Yuya Yoshida, Sakura Taniguchi, Kota Ouchi, Keigo Komine, Hiroo Imai, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Sparad:
Titel | Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab |
---|---|
Författarna | Yuki Kasahara, Ken Saijo, Reio Ueta, Ryunosuke Numakura, Keiju Sasaki, Yuya Yoshida, Sakura Taniguchi, Kota Ouchi, Keigo Komine, Hiroo Imai, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka |
Utgivningsår |
2024
|
Källa |
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
|
Beskrivning |
Abstract Pembrolizumab-containing regimens are the standard first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein-to-albumin ratio (CAR) have been reported to be important prognostic factors in a variety of carcinomas, but none have been investigated in combination with pembrolizumab and chemotherapy or in first-line treatment. Seventy-four patients with R/M HNSCC received pembrolizumab-containing regimens at Tohoku University Hospital, Sendai, Japan, from April 2020 to March 2023. Patient characteristics, tumor response, overall survival (OS), progression-free survival (PFS), and laboratory findings were reviewed. Associations between NLR, CAR, and survival outcomes were analyzed. The 1-year OS and 1-year PFS rates were 60.4% and 18.1%, respectively. The disease control rate was 66.2%. In multivariate analysis, low NLR (
|
Dokumenttyp |
article
|
Språk |
English
|
Information om utgivare |
Nature Portfolio, 2024.
|
Ämnestermer | |
This result is restricted to LU affiliated users only.
Sign in or register for an institutional account to gain full access, if eligible. |